189 related articles for article (PubMed ID: 3689664)
41. Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate).
O'Rourke NP; McCloskey EV; Rosini S; Coleman RE; Kanis JA
Br J Cancer; 1994 May; 69(5):914-7. PubMed ID: 8180023
[TBL] [Abstract][Full Text] [Related]
42. Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia.
Dodwell DJ; Abbas SK; Morton AR; Howell A
Eur J Cancer; 1991; 27(12):1629-33. PubMed ID: 1782072
[TBL] [Abstract][Full Text] [Related]
43. [Diphosphonates in the treatment of hypercalcemia].
Delmas PD; Meunier PJ
Rev Med Interne; 1984 Nov; 5(4):363-6. PubMed ID: 6240753
[TBL] [Abstract][Full Text] [Related]
44. Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study.
Body JJ; Dumon JC; Piccart M; Ford J
J Bone Miner Res; 1995 Aug; 10(8):1191-6. PubMed ID: 8585422
[TBL] [Abstract][Full Text] [Related]
45. Treatment of malignant hypercalcaemia.
Hurtado J; Esbrit P
Expert Opin Pharmacother; 2002 May; 3(5):521-7. PubMed ID: 11996631
[TBL] [Abstract][Full Text] [Related]
46. Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcemia.
Ostenstad B; Andersen OK
Acta Oncol; 1992; 31(8):861-4. PubMed ID: 1290634
[TBL] [Abstract][Full Text] [Related]
47. Long-term control of hypercalcaemia in an infant with williams-Beuren syndrome after a single infusion of biphosphonate (Pamidronate).
Oliveri B; Mastaglia SR; Mautalen C; Gravano JC; Pardo Argerich L
Acta Paediatr; 2004 Jul; 93(7):1002-3. PubMed ID: 15303821
[TBL] [Abstract][Full Text] [Related]
48. Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment.
Elte JW; Bijvoet OL; Cleton FJ; van Oosterom AT; Sleeboom HP
Eur J Cancer Clin Oncol; 1986 Apr; 22(4):493-500. PubMed ID: 2942409
[TBL] [Abstract][Full Text] [Related]
49. A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate.
Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
J Bone Miner Res; 1986 Dec; 1(6):555-62. PubMed ID: 3503561
[TBL] [Abstract][Full Text] [Related]
50. Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions.
Body JJ; Magritte A; Seraj F; Sculier JP; Borkowski A
J Bone Miner Res; 1989 Dec; 4(6):923-8. PubMed ID: 2692407
[TBL] [Abstract][Full Text] [Related]
51. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.
Hortobagyi GN; Theriault RL; Lipton A; Porter L; Blayney D; Sinoff C; Wheeler H; Simeone JF; Seaman JJ; Knight RD; Heffernan M; Mellars K; Reitsma DJ
J Clin Oncol; 1998 Jun; 16(6):2038-44. PubMed ID: 9626201
[TBL] [Abstract][Full Text] [Related]
52. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).
Harinck HI; Papapoulos SE; Blanksma HJ; Moolenaar AJ; Vermeij P; Bijvoet OL
Br Med J (Clin Res Ed); 1987 Nov; 295(6609):1301-5. PubMed ID: 3120987
[TBL] [Abstract][Full Text] [Related]
53. Hypercalcaemia of melanoma: incidence, pathogenesis and therapy with bisphosphonates.
des Grottes JM; Dumon JC; Body JJ
Melanoma Res; 2001 Oct; 11(5):477-82. PubMed ID: 11595884
[TBL] [Abstract][Full Text] [Related]
54. Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate.
Selby PL; Davies M; Marks JS; Mawer EB
Clin Endocrinol (Oxf); 1995 Nov; 43(5):531-6. PubMed ID: 8548936
[TBL] [Abstract][Full Text] [Related]
55. Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis.
Ralston SH; Hacking L; Willocks L; Bruce F; Pitkeathly DA
Ann Rheum Dis; 1989 May; 48(5):396-9. PubMed ID: 2658875
[TBL] [Abstract][Full Text] [Related]
56. Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial.
Thürlimann B; Waldburger R; Senn HJ; Thiébaud D
Ann Oncol; 1992 Sep; 3(8):619-23. PubMed ID: 1450043
[TBL] [Abstract][Full Text] [Related]
57. One-shot high-dose pamidronate disodium (APD): effective, simple treatment for hypercalcaemia in haematological malignancy.
Sawyer N; Newstead C; Drummond A; Newland A; Cunningham J
Clin Lab Haematol; 1989; 11(3):179-84. PubMed ID: 2591149
[TBL] [Abstract][Full Text] [Related]
58. Intravenous pamidronic acid in hypercalcemia due to parathyroid carcinoma.
Vega EM; Mautalen CA
Medicina (B Aires); 1991; 51(2):106-10. PubMed ID: 1820495
[TBL] [Abstract][Full Text] [Related]
59. Urinary excretion of aminohydroxypropylidene bisphosphonate in cancer patients after single intravenous infusions.
Redalieu E; Coleman JM; Chan K; Seaman J; Degen PH; Flesch G; Brox A; Batiste G
J Pharm Sci; 1993 Jun; 82(6):665-7. PubMed ID: 8331545
[TBL] [Abstract][Full Text] [Related]
60. Effects of amino-butylidene diphosphonate in hypercalcemia due to malignancy.
Bickerstaff DR; O'Doherty DP; McCloskey EV; Hamdy NA; Mian M; Kanis JA
Bone; 1991; 12(1):17-20. PubMed ID: 2054231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
